What is Barrington Research’s Forecast for ANIK Q1 Earnings?

Anika Therapeutics, Inc. (NASDAQ:ANIK) – Analysts at Barrington Research issued their Q1 2026 EPS estimates for Anika Therapeutics in a research note issued to investors on Thursday, March 13th. Barrington Research analyst M. Petusky expects that the biotechnology company will post earnings of ($0.16) per share for the quarter. Barrington Research has a “Outperform” rating and a $20.00 price objective on the stock. The consensus estimate for Anika Therapeutics’ current full-year earnings is ($0.84) per share. Barrington Research also issued estimates for Anika Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2027 earnings at ($0.45) EPS.

Separately, StockNews.com raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, March 13th.

Anika Therapeutics Trading Down 1.6 %

NASDAQ ANIK opened at $15.86 on Monday. The company has a fifty day simple moving average of $16.91 and a 200 day simple moving average of $19.33. The company has a market cap of $232.29 million, a P/E ratio of -2.38 and a beta of 0.95. Anika Therapeutics has a 1 year low of $14.95 and a 1 year high of $29.12.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13). The firm had revenue of $30.60 million during the quarter, compared to analyst estimates of $29.00 million. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%.

Institutional Trading of Anika Therapeutics

A number of hedge funds have recently bought and sold shares of ANIK. R Squared Ltd bought a new stake in Anika Therapeutics in the 4th quarter valued at $27,000. Aquatic Capital Management LLC acquired a new stake in Anika Therapeutics in the 4th quarter valued at about $42,000. Tower Research Capital LLC TRC increased its position in Anika Therapeutics by 412.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,890 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,326 shares in the last quarter. Wells Fargo & Company MN increased its position in Anika Therapeutics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,421 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 1,759 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in Anika Therapeutics in the 4th quarter valued at about $137,000. 91.53% of the stock is owned by institutional investors.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.